 Connection
Robert Griffin to Mice, Nude
This is a "connection" page, showing publications Robert Griffin has written about Mice, Nude.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.363 |
|
|
|
-
Przybyla BD, Shafirstein G, Vishal SJ, Dennis RA, Griffin RJ. Molecular changes in bone marrow, tumor and serum after conductive ablation of murine 4T1 breast carcinoma. Int J Oncol. 2014 Feb; 44(2):600-8.
Score: 0.107
-
Griffin RJ, Williams BW, Bischof JC, Olin M, Johnson GL, Lee BW. Use of a fluorescently labeled poly-caspase inhibitor for in vivo detection of apoptosis related to vascular-targeting agent arsenic trioxide for cancer therapy. Technol Cancer Res Treat. 2007 Dec; 6(6):651-4.
Score: 0.071
-
Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007 Jun 01; 13(11):3395-402.
Score: 0.068
-
Dings RP, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer. 2005 Jun 10; 115(2):312-9.
Score: 0.059
-
Nolan J, Sarimollaoglu M, Nedosekin DA, Jamshidi-Parsian A, Galanzha EI, Kore RA, Griffin RJ, Zharov VP. In Vivo Flow Cytometry of Circulating Tumor-Associated Exosomes. Anal Cell Pathol (Amst). 2016; 2016:1628057.
Score: 0.033
-
Shenoi MM, Iltis I, Choi J, Koonce NA, Metzger GJ, Griffin RJ, Bischof JC. Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy. Mol Pharm. 2013 May 06; 10(5):1683-94.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|